Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Johnson & Johnson (JNJ)

Johnson & Johnson Q4 sales rise 9.1% to $24.6 billion; 2026 guidance $100.5 billion

Positive Impact 3 of 5 earnings Written later

Johnson & Johnson reported fourth-quarter 2025 reported sales of $24.6 billion, up 9.1% from a year earlier, and full-year 2025 sales of $94.2 billion, up 6.0%. The company also issued 2026 guidance with estimated reported sales of $100.5 billion at the midpoint, a 6.7% increase, and adjusted EPS of $11.53 at the midpoint, a 6.9% increase.

Key points

  • Q4 2025 reported EPS was $2.10 versus $1.41 a year earlier; adjusted EPS was $2.46 versus $2.04
  • Full-year 2025 reported EPS was $11.03 versus $5.79; adjusted EPS was $10.79 versus $9.98
  • Q4 and full-year 2025 EPS each include a $(0.10) impact from the acquisition of Halda Therapeutics
  • 2026 guidance: estimated reported sales of $100.0 billion to $101.0 billion and adjusted EPS of $11.43 to $11.63

The filing

CompanyJohnson & Johnson (JNJ)
Form8-K, current report
Filed with the SECJan 21, 2026, 7:46 AM ET
Accession number0000200406-26-000002

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.